SI9520044B - Inhibitorji Xa faktorja - Google Patents
Inhibitorji Xa faktorja Download PDFInfo
- Publication number
- SI9520044B SI9520044B SI9520044A SI9520044A SI9520044B SI 9520044 B SI9520044 B SI 9520044B SI 9520044 A SI9520044 A SI 9520044A SI 9520044 A SI9520044 A SI 9520044A SI 9520044 B SI9520044 B SI 9520044B
- Authority
- SI
- Slovenia
- Prior art keywords
- chg
- arg
- paph
- leu
- pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (18)
1 Patentni zahtevki 1. Spojina, ki specifično zavira aktivnost Xa faktorja, s splošno formulo X,-R1-R2-R3-X2 kjer je Xi H, acil, alkil ali arilalkil; R1 je Tyr; R2 je Ile; R3 je Arg; in je X2 izbran iz skupine, ki jo sestavljajo modificirana C-terminalna skupina, ena ali več karboksi zaščitnih skupin in ena ali več amino kislin ali druga substituenta, kjer je modificirana C-terminalna skupina modificiran^ z redukcijo C-konČne karboksi skupine v alkohol ali aldehid ali s tvorbo oralnega estra ali s substitucijo karboksi skupine s substituento, vključno njene farmacevtsko sprejemljive soli.
2. Spojina, ki specifično zavira aktivnost Xa faktorja, s splošno formulo A1-A2-A3-B kjer je Al Tyr, F(pNH2) mAph, pAph ali Nal (2), ki vsebuje 0 ali 1 amino zaščitno skupino; A2 je Ile ali Chg; A3 je Arg, PalMe (3), Dab (Ny-C3H7N), Dap (NP-C3H7N) ali Om (N3-C3H7N); in je B -H, -OH, -NH2, ena do pet amino kislin ali karboksi zaščitna skupina; 2 vključno njene farmacevtsko sprejemljive soli.
3. Spojina po zahtevku 1 ali 2, kjer je amino zaščitna skupina izbrana iz skupine, ki jo sestavljajo formil, acetil, pikoloil, terc-butilacetil, terc-butiloksikarbonil, benziloksikarbonil, 2-aril-2-0-benziloksim, aminoacil, benzoil, tožil, 3-fenoksiproprionična, 5-benzimidazolkarboksi, CClF2-CO, CF2H-CO, CF3-CF2CO, CH3-CHCI-CO, CH3-O-CO, CH3-SO2, ch3ch2-o-co, Cl2CHCO, C1CH2C0, (pOH)C6H4-CH2CH(OH)-CO, (pOH)C6H4-CH2CHOH-CO, (pOHjOsH,-OCH(CH3)CO, (pOH)C6H4-OCH2CO, 4-MeO-C6H4-CO, N-morfolinil-CO, Ph-C(NOCH2Ph)-CO, Ph-CH=CH-CO, Ph-CH2CH2CH2-CO, Ph-CH2CH2CO, trifluoroacetil, ali je substitucija N-končne amino skupine s ciklopentilkarboksi, izokinolilkarboksi ali pirazinkarboksi skupino.
4. Spojina po zahtevkih 1 do 3, kjer je farmacevtsko sprejemljiva sol kislinska adicijska sol.
5. Spojina po zahtevku 4, kjer je kislinska adicijska sol sol, tvorjena z anorgansko kislino, izbrano iz skupine, ki jo sestavljajo klorovodikova kislina, bromovodikova kislina, fosforjeva kislina, žveplova kislina ali perklorova kislina, ali je sol, tvorjena z organsko kislino, izbrano iz skupine, ki jo sestavljajo ocetna kislina, oksalna kislina, maleinska kislina, jabolčna kislina, vinska kislina, citronska kislina, jantarjeva kislina ali malonska kislina.
6. Spojina po zahtevkih 1 do 5, kjer je farmacevtsko sprejemljiva sol izbrana iz skupine, ki jo sestavljajo anorganski nitrat, sulfat, acetat, malat, format, laktat, tatrat, sukcinat, citrat in p-toluensulfonat.
7. Spojina po zahtevku 6, kjer je farmacevtsko sprejemljiva sol p-toluensulfonat. 3
8. Spojina po zahtevkih 1 in 3 do 7, kjer je Xi izbran iz skupine, ki jo sestavljajo metil, etil, n-propil, izopropil, sek-butil, 1-metilbutil, 2,2-dimetilbutil, 2-metilpentil, 2,2-dimetilpropil, n-pentil, n-heksil, ciklopentil, cikloheksil, metil-cikoheksil in ciklopropil-metilen, formil, acetil, benzoil, benzil, pikolil.
9. Spojina po zahtevkih 1 in 3 do 7, kjer je oralni ester izbran iz skupine, ki jo sestavljajo alkoksimetilne skupine, a-(Ci do C4)alkoksietilne skupine, 2-okso-l,3-dioksolen-4-ilmetilne skupine, C! do C3alkiltiometilne skupine, aciloksimetilne skupine, α-aciloksi-a-substituirane metilne skupine, l-(Ci do C4) alkiloksikarboniloksi)et-l-ilne skupine in l-(Ci do C4 alkilaminokarboniloksi)et-l-ilne skupine.
10. Spojina po zahtevku 9, kjer je oralni ester izbran iz skupine, ki jo sestavljajo metoksimetil, etoksimetil, izo-propoksimetil, metoksietil, etoksietil, propoksietil, izopropoksietil, 5-metil-2-okso-l,3-dioksolen-4-ilmetil, 5-fenil-2-okso-l,3-dioksolen-4-ilmetil, metiltiometil, etiltiometil, izopropiltiometil, pivaloiloksimetil, a-acetoksimetil, etoksikarbonil-1-metil, α-acetoksietil, 3-ftalidil, 5,6-dimetilftalidil, 1-(etoksikarboniloksi)et-1 -il in 1 -(metilaminokarboniloksi)et-1 -il.
11. Spojina po zahtevkih 1 do 10, izbrana iz skupine, ki jo sestavljajo CF3C (O) - (iBu) Phe (NH2) -Chg-Arg-Leu-Pro-NH2; Ac-pAph-Ile-Arg-Leu-Pro-NH2; CF3C(0) - (iBu)Nal (2) -Chg-Arg-Leu-Pro-NH2; Ac-Phe (31,4NH2) -Chg-Arg-Leu-Pro-NH2; 4 CF3Č,(0) -Tyr-Chg- Arg-Leu-Pro-NH2; (5 -benzimidazoii. j -Phe (NH2) -Chg - Ar g - Leu - Pr o - NH2 ; CF3C(0) - (iBu)Tyr-Ile-Arg~Leu-Pro-NH2; Ac- (Chx-CHa) Tvr-Ile-Arg-Leu-Pro-NHj; D - Tyx - Chg - Arg-Leu - Pr o - NH2 ; Ac - Trp - Chg-Arg- Leu- Pro-NH2 ; Ac -pAph - Chg - Arg - Leu - Pro - NH2 ; Ac -pAph - Chg - Arg - Gla - Pro -NHa ; Ac - (iBu)Nal (2) -Ghg-Arg-Leu-Pro-NH2; Ac-Phe (p-CONHa) -Chg-Arg-Leu-Pro-NHa; Ac -pAph- Ile-Arg-heu-Pro-NHj; Ac-Phe (pNHa) -Chg-Arg- (Me) Leu-Pro-NH2; Ac- (Chx-CHs)Tyr-Chg-Arg-Leu-Pro-NHa; Ac-pAph-Chg-Pal (3) Me-Leu-Pro-NR, ; (benzoil)- Phe (pNH,) -Chg-Arg~Leu-Pro-NH2; Ac- (2-metilpentanil) - Tyx -1 le - Arg - Leu -Pro- NH2 ; Ac- (2-metilbutil) Tyr-Ile-Arg-Leu-Pxo-NH2; Ac - Phe (pNHj) - Chg - Arg - Leu - Pro - NH2 ; Ac-Tyx-Chg-Arg-Leu-Pro-NH2 ; Ac-(iBu)-Phe(pNHj)-Chg-Arg-Leu-Pro-NH2; Ac- (Chx-CHa) -Tyr-Ile-Arg-Leu-Pro-NH2.; (2-benzofuroil)- pAph-Chg-Pal (3) Me-NH2; Ac- (iBu)Phe (pNH2) -Chg-Arg-NH2; Ac -pAph- Chg - Arg - NH2 / CF3C{0) - (iBu) Phe (pNH2) - Chg-Arg-NH2; Ac - pAph- Chg - Arg - NH2 ; Ac -pAph- Chg - Pal (3) Me -NH2 ; CF3C (O) (iBu) -Tyr-Ile-Arg-NH2; Ac-pAph-Chg-PalMe (3) -NH-CHa-Chx; Ac-pAph-Chg-PalMe(3)-NH-2CMT; Ac-pAph-Chg-PalMe(3)-NH-Chx; Ac-F(pNH2) -Chg-Dah(NV-C3NH7) -L-P-NHa; Bz-F (pNH2) -Chg-R-L-P-NH2; 5 TOS-FipNHa) -Chg-R-Ii-P-NH^; Ac-Y(3-1) -Chg-R-1,-P-NH2; y-Chg-R-L-NH^· Ac-F(pNH2)-Chg-R-ol; ciklopentil -CO-pAph-Chg-PalMe (3) -NRj,; 3-Xqc-pAph-Chg-PalMe {3)-NK,; Bzf-pAph-Chg-PalMe (3) -NH2; 3-Igc-F(pNH2) -Chg-R-L-P-NH2; Ac-F(pNH2) -Chg-R-HH-2~ tiazolil 2-furoil- 1-pAph-Chg-PalMe (3) -NH2; 5-Me-2- nienil .-CO-pAph-Chg-PalMe(3) -NH2; Ac -Nal (2} -Chg-R-NH-2-tiazolil; 2-Bzf ~F(pNH2) -Chg-R-L-P-NH2; Ac-pAph-Chg-Dab ΟΤ^Ή-,Ν) -L-P-NH2; Ac- (iBu)pAph-Chg-R-L-P-NH2; Ac-pAph-Chg-R-Gla-P-NHj,; Ac-pAph-Chg-R-Pen (CH2COOH) -P-NH*; Ac-pAph-Chg-R-L-P-NH2; Ac-F (pNH2) -Chg-R- (Me)L-P-NH2; Ac-F(pNH2)-Chg-R-OEt; · . Ac-FlpNHj) -Chg-Om (N*-C3H7N.) -L-P-NH2; Ac-F (pNH2) -Chg-R-L-P-NH2; Ac-Nal (2) -Chg-R-L-P-NHj ; Ac-pAph-Chg-Dab (NY-C3H7N) -NH2; Ac-pAph-Chg-PalMe(3) -NH2; Ac-pAph-Chg-PalMe (3) -L-P-NH2; Ac - pAph- Chg - R -NH2 ; Ac-pAph-Chg-R-OH; DIPA- (m)pAph-Chg-R-L-P-NH2? DIPA- (m) F (pNH2) -Chg-R-Ii-P-NB^; Isn-F(pNH2) -Chg-R-L-P-NH2; Pza-F (pNH2) -Chg-R-L-P-NH2; Tfa- (iBu)Y-Chg-R-L-P-NH2; 6 Tfa-(iBu) Y-I-0:m(I^-C2H7N)-L-P-NHj,* Ac-pAph-Chg-PalMe (3) -NH-CH,-Chx; Ac-pAph-Chg-PalMe (3) -NH-Chx; Bzf-pAph-Chg-PalMe (3) -NHj; Ac-pAph-Chg-PalMe (3) -L-P-NH2; Ac -pAph- Chg- PalMe (3) -NH2 ; ciklopentil -CO-pAph-Chg-PalMe(3) -NH2; 3 -lqc-pAph-Chg-PalMe (3}-NH2; 2-furoil- pAph- Chg- PalMe {3) -NH2 ; 5-Me -tienil- -CO-pAph-Chg-PalMe{3)-NK^; Ac-pAph-Chg-PalMe (3)-ol; Ac - Tyr-Ile-Arg-Leu-Ala-NH2, Ac-Tyr-Ile-Arg-Leu-Pro-NH2, Ac- (iBu) Tyr-Ile-Arg-Leu-Pro-NH2, Ac-Tyr-Ile-Arg-N(CH3) 0(CH3) , Ac-iyr- {¥{CH2NH) }-Ile-Arg-Leu-Pro-£[H2i Ac-Tyx-lle-Arg-NH-CH2 (4-piridil), Ac-Tyr-Ile- {Ψ (CH2NH) } -Arg-Leu-Pro-NH2, Ac-Tyr-Chg-Arg(NO.,) -{Ψ(CHjNH) J-Leu-NIij, Ac-Tyr-Ile-Arg-{y (COCH2)} -Gly-Pro-NH2, . . Αο-ΤγΓ-ΙΙθ-ΟΒίιίΝ^^ΗτΝ) -Leu-Ala-NH2, Ac-Tyr-Ile-PalMe (3) Tyr-Ile-Arg-NH2, D - Tyr -11 e - Ar g - Leu ~ Pr o - NH 2, Ac-(Bzl)Gly-(Chx)Gly- (3-gvanidopropil); Gly-NH2, Cyclo(Gly-Tyr-Ile~Arg-Gly) , Tfa- (iBu) Tyr-Chg-Arg-Leu-Pro-NH2, Ac -pAph- Chg - Ar g- Leu - Pro -NH2, Ac-Nal (2) -Chg-Arg-Leu-Pro-NH2, Ac-pAph - Chg-PalMe-NHj ( Ac-P-pAph-Chg-Pal (Me) -Leu-Pro-NH2, Ac-D-pAph-Chg-Pal (Me) -NH2, and Ac-Phe(pNH2) -Chg-Arg-Leu-Pro-NHj.
12. Farmacevtski sestavek, ki vsebuje spojino po zahtevkih 1 do 11. 7
13. Farmacevtski sestavek po zahtevku 12, ki nadalje obsega farmacevtsko sprejemljiv nosilec.
14. Uporaba spojine po kateremkoli od zahtevkov 1 do 11 za pripravo farmacevtskega sestavka za specifično inhibiranje aktivnosti faktorja Xa.
15. Uporaba po zahtevku 14, kjer je farmacevtski pripravek za zdravljenje kardiovaskularne motnje, izbrane iz skupine, ki jo sestavljajo restenoza po angioplastiji, sindrom respiratorne stiske odraslega, multi-organska odpoved, kap in motnja razsejanega intravaskulamega koagulacijskega strjevanja.
16. Uporaba po zahtevku 14, kjer je farmacevtski pripravek za zdravljenje komplikacij, povezanih s kirurškimi ukrepi, ki so izbrane iz skupine, ki jo sestavljata globoka venska in proksimalna venska tromboza.
17. Uporaba v zahtevku 14, kjer je farmacevtski pripravek za zmanjšanje ali zaviranje strjevanja krvi.
18. Uporaba spojine po kateremkoli od zahtevkov 1 do 11 kot antikoagulant za preprečevanje koagulacije krvnega vzorca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23305494A | 1994-04-26 | 1994-04-26 | |
PCT/US1995/005268 WO1995029189A1 (en) | 1994-04-26 | 1995-04-25 | FACTOR Xa INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9520044A SI9520044A (en) | 1997-10-31 |
SI9520044B true SI9520044B (sl) | 2004-08-31 |
Family
ID=22875692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9520044A SI9520044B (sl) | 1994-04-26 | 1995-04-25 | Inhibitorji Xa faktorja |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP0758341B1 (sl) |
JP (1) | JP3655632B2 (sl) |
KR (1) | KR100380124B1 (sl) |
CN (1) | CN1181091C (sl) |
AT (1) | ATE262536T1 (sl) |
AU (1) | AU707653B2 (sl) |
CA (1) | CA2186497C (sl) |
CZ (1) | CZ296439B6 (sl) |
DE (1) | DE69532754T2 (sl) |
DK (1) | DK0758341T3 (sl) |
EE (1) | EE03973B1 (sl) |
ES (1) | ES2214500T3 (sl) |
FI (1) | FI120494B (sl) |
HU (1) | HUT76346A (sl) |
IL (1) | IL113505A (sl) |
LT (1) | LT4218B (sl) |
LV (1) | LV11740B (sl) |
NO (1) | NO318759B1 (sl) |
NZ (1) | NZ284977A (sl) |
PL (1) | PL188132B1 (sl) |
PT (1) | PT758341E (sl) |
RU (1) | RU2152954C1 (sl) |
SI (1) | SI9520044B (sl) |
SK (1) | SK286094B6 (sl) |
TW (1) | TW409129B (sl) |
WO (1) | WO1995029189A1 (sl) |
ZA (1) | ZA953361B (sl) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ302649A (en) * | 1995-02-17 | 2000-01-28 | Basf Ag | Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof |
US6069130A (en) | 1995-06-07 | 2000-05-30 | Cor Therapeutics, Inc. | Ketoheterocyclic inhibitors of factor Xa |
US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
PL185541B1 (pl) * | 1995-12-20 | 2003-05-30 | Aventis Pharmaceuticals | Sposób wytwarzania N-acetylo-(L)-4-cyjanofenyloalaniny i N-acetylo-(L)-p-amidynofenyloalaninocykloheksyloglicyno-beta-(3-N-metylopirydynio)-alaniny |
US5766932A (en) * | 1995-12-20 | 1998-06-16 | Hoechst Marion Roussel, Inc. | Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin |
US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6194435B1 (en) | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
WO1998046627A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
US6133256A (en) * | 1997-04-14 | 2000-10-17 | Cor Therapeutics Inc | Selective factor Xa inhibitors |
WO1998046626A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
US7109326B2 (en) | 1997-04-15 | 2006-09-19 | Genentech, Inc. | Halo-alkoxycarbonyl prodrugs |
US6333321B1 (en) | 1997-08-11 | 2001-12-25 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6218382B1 (en) | 1997-08-11 | 2001-04-17 | Cor Therapeutics, Inc | Selective factor Xa inhibitors |
GB9727123D0 (en) * | 1997-12-22 | 1998-02-25 | Int Centre Genetic Eng & Bio | Synthesis of diamines |
KR100608472B1 (ko) | 1997-12-24 | 2006-08-09 | 사노피-아벤티스 도이칠란트 게엠베하 | 인자 Xa의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물 |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
EP1022268A1 (en) * | 1999-01-02 | 2000-07-26 | Aventis Pharma Deutschland GmbH | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
EP1016663A1 (en) * | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
CA2358581C (en) * | 1999-01-02 | 2010-02-02 | Aventis Pharma Deutschland Gmbh | Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them |
TR200101903T2 (tr) * | 1999-01-02 | 2001-11-21 | Aventis Pharma Deutschland Gmbh | Yeni malonik asit türevleri, bunların preparasyon işlemleri. |
EP1059302A1 (en) * | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
JP5088598B2 (ja) * | 1999-12-14 | 2012-12-05 | 昭和電工株式会社 | シアノベンジルアミン類の塩の製造方法 |
CN1172905C (zh) * | 1999-12-14 | 2004-10-27 | 昭和电工株式会社 | 生产氰基苄胺盐的方法 |
WO2001055175A2 (en) * | 2000-01-28 | 2001-08-02 | Aventis Pharma Deutschland Gmbh | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides |
EP1127884A1 (en) | 2000-02-26 | 2001-08-29 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
DE10029015A1 (de) | 2000-06-15 | 2001-12-20 | Curacyte Ag | Hemmstoffe für den Gerinnungsfaktor Xa |
RU2003120070A (ru) * | 2000-12-06 | 2004-12-27 | Авентис Фармаа Дойчланд Гмбх (De) | Производные гуанидина и амидина в качестве ингибиторов фактора ха |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
JP4898091B2 (ja) | 2002-03-11 | 2012-03-14 | ザ メディシンズ カンパニー (ライプツィヒ) ゲーエムベーハー | ウロキナーゼの阻害剤、それらの製造および使用 |
PT1569912E (pt) | 2002-12-03 | 2015-09-15 | Pharmacyclics Llc | Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
EP1479680A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
DE10342108A1 (de) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
AU2005299693B2 (en) | 2004-10-26 | 2012-07-05 | Janssen Pharmaceutica, N.V. | Factor Xa compounds |
EP1724269A1 (en) | 2005-05-20 | 2006-11-22 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors |
DE102005044319A1 (de) | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
EP1918718A1 (de) * | 2006-10-31 | 2008-05-07 | Roche Diagnostics GmbH | Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben |
EP2591783A1 (en) | 2007-04-13 | 2013-05-15 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275153A (en) * | 1978-08-03 | 1981-06-23 | American Hospital Supply Corporation | Analytical fluorogenic substrates for proteolytic enzymes |
CA1161431A (en) * | 1979-05-11 | 1984-01-31 | Lars G. Svendsen | Tripeptide derivatives |
US4469679A (en) * | 1983-02-16 | 1984-09-04 | Smithkline Beckman Corporation | Octapeptide vasopressin antagonists |
HU191961B (en) * | 1984-08-02 | 1987-04-28 | Richter Gedeon Vegyeszet | Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity |
DE69321344D1 (de) * | 1992-02-14 | 1998-11-05 | Corvas Int Inc | Inhibitoren der thrombose |
-
1995
- 1995-04-25 CA CA002186497A patent/CA2186497C/en not_active Expired - Fee Related
- 1995-04-25 CZ CZ0314096A patent/CZ296439B6/cs not_active IP Right Cessation
- 1995-04-25 NZ NZ284977A patent/NZ284977A/en not_active IP Right Cessation
- 1995-04-25 RU RU96122647/04A patent/RU2152954C1/ru not_active IP Right Cessation
- 1995-04-25 CN CNB951928112A patent/CN1181091C/zh not_active Expired - Fee Related
- 1995-04-25 ES ES95917736T patent/ES2214500T3/es not_active Expired - Lifetime
- 1995-04-25 AU AU23683/95A patent/AU707653B2/en not_active Ceased
- 1995-04-25 EE EE9600146A patent/EE03973B1/xx not_active IP Right Cessation
- 1995-04-25 AT AT95917736T patent/ATE262536T1/de not_active IP Right Cessation
- 1995-04-25 SI SI9520044A patent/SI9520044B/sl not_active IP Right Cessation
- 1995-04-25 DK DK95917736T patent/DK0758341T3/da active
- 1995-04-25 KR KR1019960706004A patent/KR100380124B1/ko not_active IP Right Cessation
- 1995-04-25 EP EP95917736A patent/EP0758341B1/en not_active Expired - Lifetime
- 1995-04-25 HU HU9602954A patent/HUT76346A/hu not_active Application Discontinuation
- 1995-04-25 PT PT95917736T patent/PT758341E/pt unknown
- 1995-04-25 WO PCT/US1995/005268 patent/WO1995029189A1/en active IP Right Grant
- 1995-04-25 ZA ZA953361A patent/ZA953361B/xx unknown
- 1995-04-25 SK SK1366-96A patent/SK286094B6/sk not_active IP Right Cessation
- 1995-04-25 JP JP52785395A patent/JP3655632B2/ja not_active Expired - Fee Related
- 1995-04-25 EP EP03021617A patent/EP1384725A3/en not_active Withdrawn
- 1995-04-25 DE DE69532754T patent/DE69532754T2/de not_active Expired - Lifetime
- 1995-04-26 IL IL11350595A patent/IL113505A/xx not_active IP Right Cessation
- 1995-05-11 TW TW084104681A patent/TW409129B/zh active
-
1996
- 1996-09-25 PL PL95317067A patent/PL188132B1/pl not_active IP Right Cessation
- 1996-10-25 FI FI964317A patent/FI120494B/fi not_active IP Right Cessation
- 1996-10-25 LT LT96-151A patent/LT4218B/lt not_active IP Right Cessation
- 1996-10-25 NO NO19964553A patent/NO318759B1/no not_active IP Right Cessation
- 1996-11-15 LV LVP-96-410A patent/LV11740B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9520044B (sl) | Inhibitorji Xa faktorja | |
Dulon et al. | Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases | |
Maquart et al. | Matrikines in the regulation of extracellular matrix degradation | |
Breschi et al. | Use of a specific MMP-inhibitor (galardin) for preservation of hybrid layer | |
Heljasvaara et al. | Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases | |
Day et al. | Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit | |
ES2567706T3 (es) | Tetrapéptidos protectores para cuidado cutáneo | |
de Bentzmann et al. | Pseudomonas aeruginosa virulence factors delay airway epithelial wound repair by altering the actin cytoskeleton and inducing overactivation of epithelial matrix metalloproteinase–2 | |
Manfro et al. | Effect of different concentrations of chlorhexidine on bond strength of primary dentin | |
UA89684C2 (ru) | Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида | |
Jiang et al. | A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation | |
Lungarella et al. | Pulmonary vascular injury in pancreatitis: evidence for a major role played by pancreatic elastase | |
AU2010200198A1 (en) | Compositions and methods for regulating phagocytosis and ICAM-1 expression | |
CN104053673A (zh) | 凝血酶结合抗体分子及其用途 | |
EP1257582B1 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity | |
Bakowska et al. | Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin‐induced lung injury | |
Prasa et al. | The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation | |
DE69426569T2 (de) | Bivalente thrombininhibitore | |
Hiwada et al. | A highly potent and long-acting oral inhibitor of human renin. | |
BR9908479A (pt) | Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio | |
US9115212B2 (en) | Bifunctional peptide | |
Taki et al. | Gastrointestinal absorption of peptide drug: quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine. | |
Ingerman-Wojenski et al. | Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719 | |
Gacko et al. | Activities of proteases in parietal thrombus of aortic aneurysm | |
AU2003294360B2 (en) | Method to increase fibronectin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20111128 |